Methods of treating chronic kidney disease with dapagliflozin
MYPI2025007196A0Undetermined Publication Date: 2022-01-27ASTRAZENECA AB
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2025007196
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-03-16
- Filing Date
- 2021-04-01
- Publication Date
- 2022-01-27
Abstract
The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. Figure 13.
Need to check novelty before this filing date? Find Prior Art
